Recently, the Center for Medical Device Evaluation (CMDE) of the State Drug Administration announced a technical evaluation report for the registration of an in vitro diagnostic reagent product. This product is the SDC2 and TFPI2 genes independently developed by Wuhan Emerson Life Technology Co., Ltd. Methylation combined detection kit (fluorescent PCR method) - Aichangkang®, the full text is as follows:
Source: Center for Medical Device Technology Evaluation, State Drug Administration
About Emerson Life TechnologyWuhan Amisen Life Technology Co., Ltd. was established in January 2015. It is a high-tech enterprise focusing on the research and development, registration, production and sales of early non-invasive detection products for high-incidence malignant tumors in the world. The company is committed to the global promotion of cancer early diagnosis technology products. , Combining epigenetics, bioinformatics, clinical big data and artificial intelligence analysis, adhering to the product concept of 'early, accurate, convenient, inclusive', it has created a new generation of tumor screening and detection technology platform and product system, leading the way It has launched a series of early non-invasive detection products covering digestive system tumors, gynecological tumors, urinary system tumors and pan-cancer types, etc., which truly realizes early, non-invasive and accurate detection of tumors, and fundamentally reduces the incidence and death of tumors. rate, nip cancer in the bud, and escort human life and health.
Focus on medical needs
Focused on struggling innovators
Emerson Life Technology, keep moving forward!
